| Circulating tumor cells predict survival in early average-to-high risk breast cancer patients B Rack, C Schindlbeck, J Jückstock, U Andergassen, P Hepp, T Zwingers, ... Journal of the National Cancer Institute 106 (5), dju066, 2014 | 680 | 2014 |
| Hematogenous dissemination of glioblastoma multiforme C Müller, J Holtschmidt, M Auer, E Heitzer, K Lamszus, A Schulte, ... Science translational medicine 6 (247), 247ra101-247ra101, 2014 | 325 | 2014 |
| Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma I Ben-Batalla, A Schultze, M Wroblewski, R Erdmann, M Heuser, ... Blood, The Journal of the American Society of Hematology 122 (14), 2443-2452, 2013 | 222 | 2013 |
| Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study V Müller, S Riethdorf, B Rack, W Janni, PA Fasching, E Solomayer, ... Breast cancer research 14, 1-8, 2012 | 215 | 2012 |
| Presence of circulating tumor cells in high-risk early breast cancer during follow-up and prognosis E Trapp, W Janni, C Schindlbeck, J Jückstock, U Andergassen, ... JNCI: Journal of the National Cancer Institute 111 (4), 380-387, 2019 | 125 | 2019 |
| Multicenter evaluation of circulating cell-free DNA extraction and downstream analyses for the development of standardized (pre) analytical work flows R Lampignano, MHD Neumann, S Weber, V Kloten, A Herdean, T Voss, ... Clinical chemistry 66 (1), 149-160, 2020 | 117 | 2020 |
| Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk for relapse: The SUCCESS trial. BK Rack, C Schindlbeck, U Andergassen, A Schneeweiss, T Zwingers, ... Journal of Clinical Oncology 28 (15_suppl), 1003-1003, 2010 | 106 | 2010 |
| Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients B Aktas, S Kasimir-Bauer, V Müller, W Janni, T Fehm, D Wallwiener, ... BMC cancer 16, 1-8, 2016 | 89 | 2016 |
| Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic … W Kassouf, A Aprikian, P Black, G Kulkarni, J Izawa, L Eapen, A Fairey, ... Canadian Urological Association Journal 10 (1-2), E46, 2016 | 68 | 2016 |
| Improved Detection of Circulating Tumor Cells in Metastatic Colorectal Cancer by the Combination of the CellSearch® System and the AdnaTest® TM Gorges, A Stein, J Quidde, S Hauch, K Röck, S Riethdorf, SA Joosse, ... PloS one 11 (5), e0155126, 2016 | 64 | 2016 |
| Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome FA Yafi, S Tanguay, R Rendon, N Jacobsen, A Fairey, J Izawa, A Kapoor, ... Urologic Oncology: Seminars and Original Investigations 32 (1), 31. e17-31. e24, 2014 | 63 | 2014 |
| Comparison of oncological outcomes for open and laparoscopic radical nephroureterectomy: results from the Canadian Upper Tract Collaboration AS Fairey, W Kassouf, E Estey, S Tanguay, R Rendon, D Bell, J Izawa, ... BJU international 112 (6), 791-797, 2013 | 59 | 2013 |
| The anti-diabetic bis (maltolato) oxovanadium (IV) decreases lipid order while increasing insulin receptor localization in membrane microdomains PW Winter, A Al-Qatati, AL Wolf-Ringwall, S Schoeberl, PB Chatterjee, ... Dalton Transactions 41 (21), 6419-6430, 2012 | 58 | 2012 |
| The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experience RJ Mason, W Kassouf, DG Bell, L Lacombe, A Kapoor, N Jacobsen, ... Urology 79 (4), 840-845, 2012 | 57 | 2012 |
| Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast … V Müller, S Riethdorf, B Rack, W Janni, PA Fasching, E Solomayer, ... Breast Cancer Research 13, 1-11, 2011 | 54 | 2011 |
| Plasma micro RNA signature is associated with risk stratification in prostate cancer patients A Al‐Qatati, C Akrong, I Stevic, K Pantel, J Awe, J Saranchuk, ... International journal of cancer 141 (6), 1231-1239, 2017 | 51 | 2017 |
| Multifocality rather than tumor location is a prognostic factor in upper tract urothelial carcinoma AK Williams, W Kassouf, J Chin, R Rendon, N Jacobsen, A Fairey, ... Urologic Oncology: Seminars and Original Investigations 31 (7), 1161-1165, 2013 | 51 | 2013 |
| The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme? L Goldenberg, A So, N Fleshner, R Rendon, D Drachenberg, M Elhilali Canadian Urological Association Journal 3 (3 Suppl 2), S109, 2009 | 50 | 2009 |
| Combined pitavastatin and dacarbazine treatment activates apoptosis and autophagy resulting in synergistic cytotoxicity in melanoma cells A Al-Qatati, S Aliwaini Oncology letters 14 (6), 7993-7999, 2017 | 48 | 2017 |
| Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor–Sensitive and-Resistant Chronic Myeloid Leukemia I Ben-Batalla, R Erdmann, H Jørgensen, R Mitchell, T Ernst, ... Clinical Cancer Research 23 (9), 2289-2300, 2017 | 44 | 2017 |
